Purpose Poly (ADP-ribose) polymerase inhibitors (PARPi) have changed the management
of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi …

Clinical investigation of poly (ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer
treatment has rapidly evolved from observations of single-agent in vitro activity of these …

High-grade serous ovarian cancer is characterized by genomic instability, with one half of all
tumors displaying defects in the important DNA repair pathway of homologous …

Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs
designed to exploit synthetic lethality, and were first introduced as a cancer-targeting …

Simple Summary Poly (ADP-ribose) polymerase (PARP) inhibitors have become an
essential part of the anticancer armamentarium in ovarian cancer. As maintenence therapy …

Inhibitors of poly (ADP-ribose) polymerase (PARP) are considered one of the most active
and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of …

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial
ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease …

PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian
cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are showing considerable promise
for the treatment of BRCA mutation–associated ovarian and breast cancer. This approach …

Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous
carcinoma (HGSOC) representing the most common histological subtype. Approximately …